



**Contra Costa Health Plan**  
**P&T Formulary Update**  
**September 2, 2022**

**Changes effective: 10/21/2022**

**Contra Costa Health Plan Pharmacy & Therapeutics (P&T) Committee Decisions**

*On September 2, 2022 the CCHP P&T Committee reviewed the following Therapeutic Classes, Drug Monographs and PA criteria for efficacy, safety, utilization, cost and safety:*

Therapeutic Class Reviews	
<ul style="list-style-type: none"> <li>• Chelating agents</li> <li>• SGLT2 Inhibitors</li> <li>• GLP-1 Agonists</li> <li>• Dry Eye Disease</li> <li>• Hepatitis B</li> </ul>	<ul style="list-style-type: none"> <li>• Laxatives</li> <li>• Pancreatic Enzymes</li> <li>• Peak Flow Meters</li> </ul>
Drug Monographs	
<ul style="list-style-type: none"> <li>• Isbrela</li> <li>• Mounjaro</li> </ul>	
Prior Authorization Criteria Updates	
<p><u>New criteria was created for the following agents:</u></p> <ul style="list-style-type: none"> <li>• Biologic Agents for Nasal Polyposis</li> </ul> <p><u>Updates were made to the criteria for the following agents:</u></p> <ul style="list-style-type: none"> <li>• Urinary Antispasmodics</li> <li>• Allergy medications</li> <li>• SGLT2 Inhibitors</li> <li>• GI agents</li> <li>• Pulmonary Biologics for Asthma and Eosinophilic conditions</li> </ul> <p><u>Criteria reviewed and unchanged:</u></p> <ul style="list-style-type: none"> <li>• Laxatives</li> <li>• Mounjaro</li> <li>• Pancreatic Enzymes</li> <li>• Peak Flow Meters</li> </ul> <p><u>CCHP formulary changes were made to the following drugs:</u></p> <ul style="list-style-type: none"> <li>• GLP-1 Agonists</li> </ul>	
Guest Speaker(s)	

<ul style="list-style-type: none"> <li>• None</li> </ul>	
<b><u>CCHP P&amp;T Committee approved the following modifications to the formulary (commercial and BHC members):</u></b>	
<b>Medication Name &amp; Dosage Strength</b>	<b>Approved Formulary Changes</b>
Desloratadine (Clarinet); Desloratadine/Pseudoephedrine (Clarinet-D)	Retire from formulary and list on online formulary as non-formulary
Invokana 100, 300mg tablets	Remains as Tier 2-QL on formulary, but metformin step therapy requirement is dropped
Jardiance (empagliflozin) 10, 25mg oral tablet	Remains as Tier 2-QL on formulary, but metformin step therapy requirement is dropped
Xigduo XR (dapagliflozin-metformin) 2.5-1000mg, 150-500mg, 5-1,000mg, 10-500mg, 10-1,000mg tablet	Remains as Tier 2-QL on formulary, but metformin step therapy requirement is dropped
Invokamet (canagliflozin-metformin) XR 50-500mg, 50-1,000mg, 150-500mg, 150-1,000mg oral tablet	Remains as Tier 2-QL on formulary, but metformin step therapy requirement is dropped
Synjardy (empagliflozin-metformin) 5-500mg, 5-1,000mg, 12.5-500mg, 12.5-1,000mg	Remains as Tier 2-QL on formulary, but metformin step therapy requirement is dropped
Synjardy XR (empagliflozin-metformin) 5-1,000mg, 10-1,000mg, 12.5-1,000mg, 25-1,000mg	Remains as Tier 2-QL on formulary, but metformin step therapy requirement is dropped
Steglujan (ertugliflozin-sitagliptin) 5-100mg, 15-100mg oral tablet	Remove from formulary to non-formulary medication
Isbrela (tenapanor)	Add to formulary navigator as Tier 3-PA required
Byetta (exenatide) pen injector	No longer require Victoza step therapy
Trulicity (dulaglutide) pen injector 3mg, 4.5mg	Add quantity limits of 2/28days; T2-ST to T2-ST-QL
Ferriprox (deferiprone) 1,000mg tablet	Add to formulary navigator as Tier 3-PA required
Viread 150, 200, 250mg tablet	Change from Tier 2-QL to Tier 3-PA required
Viread (tenofovir) 40mg/gm oral powder	Change from Tier 1 to Tier 3-PA required
Adefovir (Hepsera) 10mg tablet	Change from Tier 1 to Tier 3-PA required
<b>New Product Reviews (including new indications)</b>	
<ul style="list-style-type: none"> <li>• Igalmi (dexmedetomidine)</li> <li>• Raducava (Edaravone)</li> <li>• Mounjaro (Tirzepatide)</li> <li>• Vtama (tapinarof) 1% cream</li> <li>• Beovu (brolucizumab)</li> <li>• Byooviz (Ranibizumab-nuna)</li> </ul>	<ul style="list-style-type: none"> <li>• Olumiant (Baricitinib)</li> <li>• Ztalmy (Ganaxolone)</li> <li>• Am vuttra (vutrisiran)</li> <li>• Ticovac</li> <li>• Aspruzyo sprinkle (ranolazine)</li> <li>• Vivjoa (Oteseconazole)</li> </ul>